Advertisement

August 5, 2020

CardioMech AS Announces Series A Financing for its Transcatheter Mitral Valve Repair Technology

August 5, 2020—CardioMech AS announced it has closed on its Series A financing to support the process of a first-in-human feasibility trial for the company’s catheter-based transfemoral, transseptally delivered mitral valve repair technology to reduce or eliminate mitral regurgitation.

CardioMech AS is a privately held company based in Minneapolis, Minnesota, that is developing transcatheter technology to treat patients with moderate-to-severe or severe, symptomatic degenerative mitral regurgitation caused by prolapse or flail.

The $18.5 million financing round is led by a nondisclosed strategic investor together with health care specialist investor Hadean Ventures and Investinor.

Advertisement


August 6, 2020

Conformal Medical Secures Financing to Support Pivotal Trial of CLAAS Technology

August 5, 2020

SCAI Seeks to Challenge Reductions in Proposed CMS Payment Schedule